93 related articles for article (PubMed ID: 15261288)
21. Unraveling neuronal dopamine transporter mechanisms with rotating disk electrode voltammetry.
Schenk JO; Wright C; Bjorklund N
J Neurosci Methods; 2005 Apr; 143(1):41-7. PubMed ID: 15763135
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites.
Davies HM; Hopper DW; Hansen T; Liu Q; Childers SR
Bioorg Med Chem Lett; 2004 Apr; 14(7):1799-802. PubMed ID: 15026075
[TBL] [Abstract][Full Text] [Related]
23. L-arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism.
Volz TJ; Schenk JO
Synapse; 2004 Dec; 54(3):173-82. PubMed ID: 15452864
[TBL] [Abstract][Full Text] [Related]
24. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.
Ukairo OT; Bondi CD; Newman AH; Kulkarni SS; Kozikowski AP; Pan S; Surratt CK
J Pharmacol Exp Ther; 2005 Aug; 314(2):575-83. PubMed ID: 15879005
[TBL] [Abstract][Full Text] [Related]
25. Environmental enrichment decreases cell surface expression of the dopamine transporter in rat medial prefrontal cortex.
Zhu J; Apparsundaram S; Bardo MT; Dwoskin LP
J Neurochem; 2005 Jun; 93(6):1434-43. PubMed ID: 15935059
[TBL] [Abstract][Full Text] [Related]
26. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate.
Chen R; Han DD; Gu HH
J Neurochem; 2005 Jul; 94(2):352-9. PubMed ID: 15998286
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biodistribution of [18F]FE@CIT, a new potential tracer for the dopamine transporter.
Mitterhauser M; Wadsak W; Mien LK; Hoepping A; Viernstein H; Dudczak R; Kletter K
Synapse; 2005 Feb; 55(2):73-9. PubMed ID: 15529336
[TBL] [Abstract][Full Text] [Related]
28. Voltammetric assessment of dopamine clearance in the absence of the dopamine transporter: no contribution of other transporters in core or shell of nucleus accumbens.
Mateo Y; Budygin EA; John CE; Banks ML; Jones SR
J Neurosci Methods; 2004 Dec; 140(1-2):183-7. PubMed ID: 15589348
[TBL] [Abstract][Full Text] [Related]
29. Dopamine transporter network and pathways.
Maiya R; Mayfield RD
Int Rev Neurobiol; 2004; 61():79-96. PubMed ID: 15482812
[No Abstract] [Full Text] [Related]
30. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.
Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
Biol Psychiatry; 2005 Feb; 57(3):229-38. PubMed ID: 15691523
[TBL] [Abstract][Full Text] [Related]
31. The dopamine transporter: role in neurotoxicity and human disease.
Bannon MJ
Toxicol Appl Pharmacol; 2005 May; 204(3):355-60. PubMed ID: 15845424
[TBL] [Abstract][Full Text] [Related]
32. Further exploration of 1-[2-[Bis-(4-fluorophenyl)methoxy]ethyl]piperazine (GBR 12909): role of N-aromatic, N-heteroaromatic, and 3-oxygenated N-phenylpropyl substituents on affinity for the dopamine and serotonin transporter.
Lewis D; Zhang Y; Prisinzano T; Dersch CM; Rothman RB; Jacobson AE; Rice KC
Bioorg Med Chem Lett; 2003 Apr; 13(7):1385-9. PubMed ID: 12657288
[TBL] [Abstract][Full Text] [Related]
33. Proline mutations induce negative-dosage effects on uptake velocity of the dopamine transporter.
Lin Z; Uhl GR
J Neurochem; 2005 Jul; 94(1):276-87. PubMed ID: 15953370
[TBL] [Abstract][Full Text] [Related]
34. Sp1 and Sp3 activate transcription of the human dopamine transporter gene.
Wang J; Bannon MJ
J Neurochem; 2005 Apr; 93(2):474-82. PubMed ID: 15816870
[TBL] [Abstract][Full Text] [Related]
35. Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism.
Sorkina T; Hoover BR; Zahniser NR; Sorkin A
Traffic; 2005 Feb; 6(2):157-70. PubMed ID: 15634215
[TBL] [Abstract][Full Text] [Related]
36. Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys.
Ginsburg BC; Kimmel HL; Carroll FI; Goodman MM; Howell LL
Pharmacol Biochem Behav; 2005 Mar; 80(3):481-91. PubMed ID: 15740791
[TBL] [Abstract][Full Text] [Related]
37. Semi-automated preparation of the dopamine transporter ligand [(18)F]FECNT for human PET imaging studies.
Voll RJ; McConathy J; Waldrep MS; Crowe RJ; Goodman MM
Appl Radiat Isot; 2005 Sep; 63(3):353-61. PubMed ID: 15985372
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol.
Patrick KS; Williard RL; VanWert AL; Dowd JJ; Oatis JE; Middaugh LD
J Med Chem; 2005 Apr; 48(8):2876-81. PubMed ID: 15828826
[TBL] [Abstract][Full Text] [Related]
39. Protective effect of unsymmetrical dichalcogenide, a novel antioxidant agent, in vitro and an in vivo model of brain oxidative damage.
Prigol M; Wilhelm EA; Schneider CC; Nogueira CW
Chem Biol Interact; 2008 Nov; 176(2-3):129-36. PubMed ID: 18722362
[TBL] [Abstract][Full Text] [Related]
40. Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra.
Paris I; Martinez-Alvarado P; Perez-Pastene C; Vieira MN; Olea-Azar C; Raisman-Vozari R; Cardenas S; Graumann R; Caviedes P; Segura-Aguilar J
J Neurochem; 2005 Mar; 92(5):1021-32. PubMed ID: 15715653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
